Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Pinkie Fitts

Nurse Practitioner, Psychiatric/Mental Health Aurora, CO Nurse Practitioner

NPI 1407256217 CMS profile 10681089

2675 S Abilene St Ste 100, Aurora, CO 80014

Open in the dashboard

General payments

$443,972

675 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pinkie Fitts of Aurora, CO is reported in the CMS Open Payments database as having received $443,972 across 675 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $147,456 137
2024 General $99,123 108
2023 General $69,879 78
2022 General $85,671 155
2021 General $41,843 197

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pinkie Fitts
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Pinkie Fitts were reported at $147,456. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Pinkie Fitts Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $41,843 $166 $54–$482 $132
2022 $85,671 $195 $66–$559 $149
2023 $69,879 $233 $82–$673 $160
2024 $99,123 $236 $84–$688 $164
2025 $147,456 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Neurocrine Biosciences, Inc. $440,667 464 payments
  2. AbbVie, Inc. $548 39 payments
  3. Supernus Pharmaceuticals, Inc. $477 41 payments
  4. Alkermes, Inc. $401 20 payments
  5. Bausch Health US, LLC $319 22 payments
  6. Otsuka America Pharmaceutical, Inc. $304 21 payments
  7. Lundbeck LLC $233 12 payments
  8. ITI, Inc. $199 8 payments
  9. Sunovion Pharmaceuticals Inc. $176 9 payments
  10. Vanda Pharmaceuticals Inc. $167 8 payments
  11. Other $480 31 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $353,887 127 payments
  2. Travel and Lodging $58,454 192 payments
  3. Consulting Fee $20,251 5 payments
  4. Food and Beverage $11,334 350 payments
  5. Education $47 1 payment
Products named General payments · program years 2021–2025
  1. INGREZZA Neuropsychiatry $401,187 417 payments
  2. INGREZZA Neurology $39,480 47 payments
  3. VRAYLAR $548 39 payments
  4. QELBREE $477 41 payments
  5. WELLBUTRIN $319 22 payments
  6. APLENZIN $319 22 payments
  7. REXULTI $287 20 payments
  8. ARISTADA INITIO $273 17 payments
  9. ARISTADA Cns $273 17 payments
  10. ARISTADA Cns $273 17 payments
  11. Other $2,820 143 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

441

Median for Nurse Practitioner: 389

Drug cost

$113,460

Median for Nurse Practitioner: $21,885

Branded share of claims

15.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 13 $102,727
Clozapine Generic 22 $2,764
Venlafaxine Hcl Er Venlafaxine Hcl Brand 14 $1,398
Aripiprazole Generic 45 $949
Dexmethylphenidate Hcl Er Dexmethylphenidate Hcl Brand 11 $921
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 11 $644
Bupropion Xl Bupropion Hcl Brand 20 $607
Trazodone Hcl Generic 53 $545
Quetiapine Fumarate Generic 34 $523
Duloxetine Hcl Generic 16 $448

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $99,123
$99,123 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

675 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record